Cellected and Stem Genomics are collaborating to help provide
iPSC researchers with a solution for iPSCs with genomic abnormalities
- induced pluripotent stem cells (“iPSCs”) are known to develop genomic abnormalities
- Stem Genomics has developed novel techniques to detect genomic abnormalities in iPSCs – rapidly and cost-effectively – ideal for in-process Quality Control of iPSCs
- Stem Genomics latest iCS-digitalTM PSC service detects >93% of recurrent genomic abnormalities in human iPSCs, including the frequent 20q11.21 genomic abnormality
- Cellected has developed a number of specialist services for iPSCs focused around Quality Control and solutions for improving reproducibility, reliability and consistency of iPSC lines, cultures and assays
- In particular, Cellected has developed its proprietary RESCUE service, which can be deployed if Stem Genomics detects an iPSC line with a mosaic genomic abnormality: Cellected’s RESCUE can recover the wild type cells – and ‘rescue’ the iPSC line
Patricia Baptista, Stem Genomics Sales & Marketing Director said:
“Working closely with Cellected and its RESCUE service makes so much sense for our clients.”
“We are seeing rapid growth in our iCS-digitalTM PSC service – but as a result are having to inform an increasing number of clients that their critical iPSCs incorporate a genomic anomaly. However, by working with Cellected and their novel RESCUE service, we can now present a ‘solution’ to clients.”
“Everyone prefers being presented with a solution rather than a problem!”
Dr Claire Richards, CEO of Cellected said:
“We have known and admired Stem Genomics for some time and have been very impressed by their innovation and market-led approach to developing novel, cost effective and rapid solutions to Quality Control in the iPSC world.”
“Carrying out research on iPSCs is expensive – it requires highly specialist reagents and expert techniques. The cells are also highly susceptible to picking up genomic abnormalities in culture, including the common 20q11.21 anomaly. So ongoing, in-process QC is a ‘must have’ for iPSC research – and Stem Genomics’ iCS-digitalTM service is ideal for iPSC researchers: rapid, repeatable and cost-effective.”
“We are delighted that Cellected’s RESCUE service can now offer Stem Genomics’ clients a solution when their iPSCs develop genomic abnormalities. This partnership ensures that valuable iPSC lines can be recovered, preventing loss and accelerating research progress”.